SCHEMBL6955100

SCHEMBL6955100

Cc1nc(N2CCc3cc4c(cc3CC2)OCO4)c([N+](=O)[O-])c(=O)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TRPV1 Q8NER1 1/20 0.34
HTT P42858 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP3A4 P08684 1/20 0.34
MAPK1 P28482 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6952830 0.83 RAB9A (0.47) MAPTALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL6955056 0.82 PNMT (0.40) MAPTALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL6947740 0.81 TYMS (0.44) MAPTHTTKMT2A
SCHEMBL6950817 0.81 TYMS (0.44) MAPTSMN1; SMN2HTTCYP1A2CYP2C9
SCHEMBL6953047 0.81 MAPT (0.38) MAPTALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL6951360 0.79 LMNA (0.42) MAPTALDH1A1SMN1; SMN2HTTCYP2C19
SCHEMBL6948442 0.78 CA1 (0.41) MAPTALDH1A1SMN1; SMN2HTTCYP2C19
SCHEMBL6435436 0.77 MAPT (0.35) MAPTALDH1A1SMN1; SMN2HTTCYP1A2
SCHEMBL6948586 0.73 TYMS (0.44) MAPTALDH1A1SMN1; SMN2HTTCYP1A2
SCHEMBL6952355 0.73 KMT2A (0.40) SMN1; SMN2CYP1A2CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed